Intravitreal bevacizumab (Avastin) for age-related macular degeneration: A critical analysis of literature

Eye

Volumn 24, Issue 5, 2010, Pages 816-824

  Jyothi, S ^a   Chowdhury, H ^a   Elagouz, M ^a,b   Sivaprasad, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Sohag University   (Egypt)

Author keywords

Age related macular degeneration (ARMD); Anti VEGF (Vascular Endothelial Growth Factor); Avastin; Bevacizumab; Choroidal neovascularisation (CNV); Treatment regimen

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; MINOCYCLINE; TRIAMCINOLONE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; LENS DISEASE; LENS INJURY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 77952492420     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.219     Document Type: Article

References (75)

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25(2):111-118.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25(4):581-611. (Pubitemid 39099316)
3. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-2816.
4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431.
6. Liew G, Mitchell P, Gillies MC, Wong TY, Rosenfeld PJ, Brown DM et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356: 747-750.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342.
8. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration: twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005;112(6):1035-1047.
9. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-372.
10. Aggio BF, Eid Farah M, Melo GB. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Acta Ophthalmol Scand 2006;84(5):713-714.
11. von Elm E, Altman DG, Egger M, Pocock SJ, Gtzsche PC, Vandenbroucke JP. STROBE Initiative. The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370: 1453-1457.
12. STROBE Statement. Strengthening the reporting of observational studies in epidemiology. STROBE checklist, version 4 (as published in Oct/Nov. 2007). Available at: http://www.strobe-statement.org/Checklist.html. Accessed November 15, 2007.
13. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18: 805-835. (Pubitemid 350295185)
14. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285: 1987-1991. (Pubitemid 32366951)
15. Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology 2009;116(2):286-296 [epub 16 December 2008].
16. Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol 2007;245(2):215-220.
17. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007;7: 10.
18. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Ahadi H. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Eur J Ophthalmol 2008;18(2):297-300.
19. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245(7):941-948 [epub 21 December 2006].
20. Algvere PV, Steén B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86(5):482-489.
21. Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L et al, Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28(10):1387-1394.
22. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92(12):1636-1641.
23. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27(2):133-140.
24. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-372 e5.
25. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Opthalmol 2008;52(1):52-56.
26. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascularage-related macular degeneration. Arch Ophthalmol 2007;125(10):1357-1361.
27. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142(1):1-9.
28. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145(2):249-256.
29. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143(3):510-512.
30. Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007;27(4):445-450.
31. Cleary CA, Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008;22(1):82-86.
32. Costa RA, Jorge R, Calucci D, Melo Jr LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245(9):1273-1280.
33. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo Jr LA, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47(10):4569-4578.
34. De Clercq C, Snyers B, Guagnini AP, Kozyreff A. Treatment of age-related macular degeneration with intravitreous injections of bevacizumab (Avastin): short-term results. Bull Soc Belge Ophtalmol 2007;306: 15-21.
35. Dhalla MS, Shah GK, Blinder KJ, Ryan Jr EH, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26(9):988-993.
36. Ehrlich R, Weinberger D, Priel E, Axer-Siegel R. Outcome of bevacizumab (avastin) injection in patients with age-related macular degeneration and low visual acuity. Retina 2008;28(9):302-1307.
37. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27(4):439-444.
38. Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidalneovascularization in agerelated macular degeneration. Retina 2007;27(6):701-706.
39. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36(8):748-755.
40. Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L et al. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009;87(4):404-407 [epub 8 September 2008].
41. Geitzenauer W, Michels S, Prager F, Kornek G, Vormittag L, Rosenfeld P et al. Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2006;223(10):822-827. (Pubitemid 44860922)
42. Giansanti F, Virgili G, Bini A, Rapizzi E, Giacomelli G, Donati MC et al. Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. Eur J Ophthalmol 2007;17(2):230-237.
43. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007;27(4):432-438.
44. Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007;104(7):588-593.
45. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006;37(6):446-454.
46. Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007;85(5):563-565.
47. Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009;41(1):21-27 [epub 13 October 2008].
48. Krebs I, Lie S, Stolba U, Zeiler F, Felke S, Binder S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol 2008; epub ahead of print 17 October 2008.
49. Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG et al. Combined intravitreal bevacizumab and photodynamictherapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008;246: 17-25.
50. Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 2007;27(7):891-896.
51. Lazić R, Gabrić N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114(6):1179-1185.
52. Lazić R, Gabrić N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245(1):68-73.
53. Lazic R, Gabrić N, Dekaris I, Sarić B, Gavrić M. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration. Coll Antropol 2007;31 (Suppl 1):77-81.
54. Lazić R, Gabrić N, Dekaris I, Gavric M, Bosnar D. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 2007;31 (Suppl 1):71-75.
55. Levy J, Shneck M, Rosen S, Klemperer I, Rand D, Weinstein O et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2008; epub ahead of print 11 June 2008.
56. Lux A, Llacer H, Heussen FM, Joussen AM. Nonresponders to bevacizumab therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91(10):1318-1322.
57. Madhusudhana KC, Hannan SR, Williams CP, Goverdhan SV, Rennie C, Lotery AJ et al Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007;91(12):1716-1717.
58. Mackiewicz J, Mankowska A, Dolar-Szczasny J, Zubilewicz A, Oleszczuk A, Nowomiejska K et al. Intravitreal bevacizumab (Avastin) injections for neovascular agerelated macular degeneration (AMD) -preliminary results. Klin Oczna 2007;109 (4-6):146-149.
59. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146(1):91-95.
60. Mones JM, Lopez MA, Prieto JA, Rodriguez JP. Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 2007;38(3):226-228.
61. Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration. Retina 2009;29(1):13-19.
62. Pedersen KB, Sjølie AK, Møller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol 2008; epub ahead of print 16 December 2008.
63. Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007;85(5):526-533 [epub 18 May 2007].
64. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Retina 2006;26(5):495-511.
65. Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 2009; epub ahead of print 23 January 2009.
66. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan Jr EH, Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008;28(5):675-681.
67. Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26: 383-390. (Pubitemid 44197628)
68. Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144(6):886-892.
69. Unver YB, Yavuz GA, Bekir N, Presti P, Li W, Sinclair SH. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Eye 2009;23(2):453-460.
70. Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92(3):356-360.
71. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26(9):994-998.
72. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247(1):1-11.
73. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90(11):1344-1349.
74. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR et al. Surveillance for potential adverse events associated with the use of intravitrealbevacizumab for retinal and choroidal vascular disease. Retina 2008;28(8):1151-1158.
75. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-583.